Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A

In open - label study, substantial increase seen in factor VIII activity at weeks 49 to 52 of follow - up
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news